Roberto Lee

Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA.

Deutsche Bank AG /UK/ (Deutsche Bank UK) is the Great Britain-based division of Deutsche Bank AG in Germany, which focuses on retail banking, proprietary management, and private wealth management for individual investors. Established in 1873, the firm is headquartered in London and offers commercial and corporate banking products and services. They promote and coordinate socially responsible activities on behalf of Deutsche Bank and their employees in Great Britain, supporting charities and community organizations within their key focus areas of education, social initiatives, and art.

Part of Piper Sandler Cos., Piper Sandler Ltd. is a brokerage services provider. The company is based in London, UK. The British company was founded in 1999. Neil Robert Mackison has been the CEO of the company since 2006.

Part of ING Groep NV, ING Barings Group LLC is a British company that provides investment banking and financial services. The company is based in London, UK.

UBS AG (London Branch) is the Great Britain-based brokerage subsidiary of UBS AG, ultimately held by UBS Group AG (SWX: UBSG) in Switzerland. Headquartered in London, the firm was founded in 1998 and provides nimble, innovative and bespoke access to solutions, from market and insight tools, to trading strategies and execution for private, institutional and corporate clients worldwide, as well as private clients in Switzerland. They distribute, trade, finance and clear cash equity and equity-linked products. The firm also structures, originates and distributes new equity and equity-linked issues.

Part of Oxford Biomedica Plc, Oxford Biomedica (UK) Ltd. is a viral vector contract development and manufacturing organization (CDMO) based in Oxford, UK. Oxford Biomedica (UK has over 25 years of experience in the industry and is committed to enabling its clients to deliver life-changing therapies to patients worldwide. The British company offers innovative solutions to cell and gene therapy biotechnology and biopharma companies by working across key viral vector delivery systems including adeno-associated virus (AAV) and lentiviral delivery system.

SYN thesis med chem Pty Ltd. engages in the development and provision of molecule drug discovery services. It offers integrated drug discovery, medicinal and synthetic chemistry, single compound synthesis, and catalogue products. The company was founded by Andrew Wilks and Xian Bu and is headquartered in Parkville, Australia.

Medicines Development Ltd. engages in the development of medicines and vaccines. Its development programs include Moxidectin Program, Global Health Programs, and Consulting ervices. The company was founded by Mark Sullivan in 2005 and is headquartered in Melbourne, Australia.

WG Partners LLP is a specialist life sciences boutique that provides corporate advisory, M&A, and capital raising services. The private company is based in London, UK, with an additional office in Sydney, Australia. The British company has completed transactions with a total value in excess of £8.2 billion and is 100% owned by the partners who combine more than 250 years of relevant experience. The company brings a truly international perspective, acting for corporate and institutional clients across Europe, the USA, and Australia. The company was founded in 2011 by David Ian Wilson.

Virocell Biologics Ltd. is an innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials. The company is based in London, UK. The British company leverages its expertise in vector manufacture directly into the production of gene-modified cells, both adherent cells such as Mesenchymal Stromal/Stem cells and suspension cultures such as CAR T-cells. Virocell Biologics is committed to leveraging its deep experience to rapidly design and select a manufacturing strategy best suited to the client's objectives. The company was founded by Farzin Farzaneh, John W. Hadden. John W. Hadden has been the CEO since incorporation.